Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2016 / Nov / Edema Enigma
Anterior Segment Cataract Retina

Edema Enigma

Have reports of NSAIDs preventing post-cataract macular edema been exaggerated?

By Ruth Steer 11/25/2016 1 min read

Share

Figure 1. Summary of key results three months post-surgery (1). CI, confidence interval.

Macular edema (ME) following cataract surgery isn’t fun for anyone. Although it’s usually self-limiting, it’s particularly bad news for patients’ vision if it persists. That’s why most surgeons like to take a prophylactic approach to ME and use topical steroids and/or topical non-steroidal anti-inflammatory drugs (NSAIDs) before and after surgery. But a recently-published Cochrane Eyes and Vision systematic review might change that perception.

Their review incorporated results from 34 randomized controlled trials that involved over 5,000 patients who received surgery for age-related cataract that reported ME incidence. Of those, 28 studies compared NSAIDs and steroids versus steroids alone, and the remaining six compared NSAIDs directly with steroids. They found:

  • At three months post-op, the risk of poor vision secondary to ME was lower in patients who received NSAIDs and steroids, than steroids alone – but this was classed as “low certainty evidence.”
  • Also classed as “low certainty” was evidence of a reduced risk of NSAIDs and ME at three months post-op.
  • Almost no evidence was found that NSAIDs improve outcomes for patients, with only one study reporting on quality of life – and even then, stated only that there was a “lack of differences between groups.”
  • Inconsistent data regarding central retinal thickness at three months post-surgery (I² = 87%), and little difference in reported BCVA outcomes (inter-group differences were less than 0.1 LogMAR in 31 out of 34 studies).
  • The most notable adverse effects associated with NSAIDs were burning or stinging; there was no evidence of serious adverse effects.

So what’s the take home message? Blanche Lim, lead author on the paper explains: “Topical NSAIDs may be beneficial as prophylaxis against ME, however there remains a lack of compelling evidence to suggest any visual benefit in the long run. There is also a paucity of data to determine effectivity in certain at-risk subgroups.” The authors note that future trials are needed to clear up the uncertainty. In the meantime, Lim comments “The inclusion of NSAIDs as a standard regimen perioperatively still remains surgeon-dependent.”

References

  1. BX Lim et al., “Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery”, Cochrane Database Syst Rev, 11 (2016). [Epub ahead of print]. PMID: 27801522.

About the Author(s)

Ruth Steer

More Articles by Ruth Steer

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: